Dakota15
Senior Member (Voting Rights)
BioVie: 'Long COVID Treatment Landscape and BioVie’s ADDRESS-LC Trial (Hosted on April 10, 2025)'
'BioVie hosted a virtual investor event on April 10, 2025 featuring key opinion leader (KOL) Lindsay McAlpine MD, Yale University, to discuss the unmet need and current treatment landscape for long COVID, as well as to provide an update on our ADDRESS-LC clinical trial. Chronic neuroinflammation, potentially driven by persisting viral spike protein, is one of the main hypotheses that has been proposed to explain the persistence of symptoms in long COVID. Our lead candidate, bezisterim (NE3107), has demonstrated the ability to modulate key inflammatory pathways implicated in the chronic inflammation seen in long COVID without inhibiting their homeostatic functions.'
'BioVie hosted a virtual investor event on April 10, 2025 featuring key opinion leader (KOL) Lindsay McAlpine MD, Yale University, to discuss the unmet need and current treatment landscape for long COVID, as well as to provide an update on our ADDRESS-LC clinical trial. Chronic neuroinflammation, potentially driven by persisting viral spike protein, is one of the main hypotheses that has been proposed to explain the persistence of symptoms in long COVID. Our lead candidate, bezisterim (NE3107), has demonstrated the ability to modulate key inflammatory pathways implicated in the chronic inflammation seen in long COVID without inhibiting their homeostatic functions.'